Edition:
United States

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

1.74USD
15 Dec 2017
Change (% chg)

$0.04 (+2.35%)
Prev Close
$1.70
Open
$1.71
Day's High
$1.74
Day's Low
$1.70
Volume
20,094
Avg. Vol
38,342
52-wk High
$4.07
52-wk Low
$0.87

Chart for

About

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The... (more)

Overall

Beta: 0.41
Market Cap(Mil.): $26.48
Shares Outstanding(Mil.): 15.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Apricus Biosciences files for mixed shelf of up to $100 million

* Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing Source text : (http://bit.ly/2gZ2TjB) Further company coverage:

Nov 02 2017

BRIEF-Apricus Biosciences files for resale of up to 3.3 mln of common stock by selling stockholders

* Apricus Biosciences Inc files for resale of up to 3.3 million of common stock by selling stockholders - SEC Filing Source text :(http://bit.ly/2y3YztZ) Further company coverage:

Sep 25 2017

BRIEF-Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in co

* Armistice Capital LLC reports 9.6 percent passive stake in Apricus Biosciences Inc, as of September 10, 2017 - SEC filing ‍​ Source text: [http://bit.ly/2xgpiTr] Further company coverage:

Sep 20 2017

BRIEF-Apricus Biosciences announces $3.7 million private placement priced at-the-market

* Apricus Biosciences announces $3.7 million private placement priced at-the-market

Sep 11 2017

BRIEF-Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission

* Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission

Aug 31 2017

BRIEF-Apricus Biosciences files NDA resubmission for Vitaros

* Apricus Biosciences Inc - Apricus anticipates a six-month review by FDA with a projected PDUFA goal date in Q1 of 2018 Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Apricus Biosciences Q2 loss per share $0.13

* Apricus Biosciences provides corporate update and second quarter 2017 financial results

Aug 02 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $37.20 +0.74
GlaxoSmithKline plc (GSK.L) 1,295.00 --
Eli Lilly and Co (LLY.N) $86.54 +0.04
Abbott Laboratories (ABT.N) $55.50 +0.77

Earnings vs. Estimates